Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

This study has been completed.
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Alexandra Kimball, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00722761
First received: July 24, 2008
Last updated: January 29, 2013
Last verified: January 2013

July 24, 2008
January 29, 2013
April 2009
April 2012   (final data collection date for primary outcome measure)
Percent Change in Truncal Lesion Counts [ Time Frame: 0-24 weeks ] [ Designated as safety issue: No ]
Acne lesion count (noninflammatory, inflammatory and total lesions) difference between week 0 (baseline) and week 24 is divided by the acne lesion count at week 0 and multiplied by 100. A positive change indicates a decrease in truncal acne lesions.
Percent Change in Truncal Lesion Counts [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00722761 on ClinicalTrials.gov Archive Site
Percentage of Subjects Rated Clear or Almost Clear on the IGA and SGA at Week 24/ Early Termination [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Percentage of subjects rated Clear (score 0) or Almost Clear (score 1) on the Investigator's Global Assessment (IGA) of truncal acne at Week 24 as well as Subject's Assessment of Acne at Week 24/Early Termination were taken. It was computed by: number of successes (those scored 0 or 1)divided by the number of participants multiplied by 100.
Percentage of subjects rated Clear or Almost Clear on the Investigator's Global Assessment (IGA) of truncal acne and of All Acne at Week 24 and Change in Truncal Lesion Counts, Subject's Assessment of Acne at Week 24/Early Termination [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy Of YAZ Compared With Placebo In The Treatment Of Moderate Truncal Acne Vulgaris

The purpose of this study is to find out if taking a birth control pill, YAZ, is safe and effective for treating acne on the trunk (the main part of the body that does not include the arms, legs, and head).

Acne vulgaris is a very common skin disorder. It is caused when oil-producing skin glands (sebaceous glands) become plugged. The plug can cause blackheads, whiteheads, pimples, and cysts on the face, neck, upper chest, and upper back.

YAZ is a combination birth control pill. A "combination" pill means that it is made up of more than one major ingredient. Nearly all birth control pills are made up of a combination of estrogen and progestin hormones. Estrogens are steroid hormones produced by the ovaries responsible for the typical female features. Progestins are steroid hormones produced by the ovary and placenta responsible for making the uterus fit for pregnancy. YAZ also contains an estrogen called ethinyl estradiol, and a progestin called drospirenone. People who develop acne have sebaceous glands that are over-stimulated (that is, the sebaceous glands have increased activity) by male sex hormones (androgens). The progestin in YAZ blocks the male sex hormones (androgens) that cause acne.

The study drug being used in this study is called YAZ. It has been approved by the U.S. Food and Drug Administration (FDA) to treat moderate acne in women who want an oral contraceptive for birth control.

In this study, YAZ will be compared to a placebo for safety and effectiveness. A placebo looks like the study drug but contains no active drug (like a sugar pill). We use placebos in research studies to learn if the effects seen in research subjects are truly from the study drug or from other reasons.

Acne is a common skin disease that affects 85-100% of the population. Although it often appears during puberty, it may persist during the third decade of life and even later. It is characterized by a variety of lesions consisting of non-inflammatory lesions known as comedones, and inflammatory lesions such as papules, pustules, nodules and cysts. It commonly occurs on the face, chest, and back. Although not as noticeable as facial acne, truncal acne may also affect a person's self esteem and body image and reduce one's participation in sports because of the need to undress in a shared locker room. Most acne studies focus on facial acne and ignore treatment outcomes in the chest and back.

The pathogenesis of acne is multifactorial, developing in the sebaceous gland. These factors include intrafollicular hypercornification, which induces follicular obstruction resulting in comedone formation, excess sebum production, Propionibacterium acnes activity and inflammation.

Hormone therapies, such as oral contraceptives and antiandrogens (e.g. spironolactone) counteract the effects of androgens on the sebaceous glands. It has been over ten years since estrogen-containing oral contraceptives (OCs) first obtained FDA approval for use in acne. Since then, several randomized controlled trials have corroborated their efficacy and safety for this growing indication in women of child bearing age. Studies have shown hormonal therapies to be effective in treating moderate acne vulgaris in women with no known contraindication to OC therapy.

YAZ is an oral contraceptive that is FDA approved for acne vulgaris. Unlike other progestins, drospirenone has unique antimineralocorticoid (mild diuretic effect) and antiandrogenic properties. The antiandrogenic property of drospirenone means that it blocks the male sex hormones that can cause acne. In two multicenter, double blind, randomized, placebo-controlled studies, 889 subjects, ages 14 to 45 years, with moderate acne received YAZ or placebo for six 28 day cycles. The primary efficacy endpoints were the percent change in inflammatory lesions, non-inflammatory lesions, total lesions, and the percentage of subjects with a "clear" or "almost clear" rating on the Investigator's Static Global Assessment (ISGA) scale on day 15 of cycle 6.

Subjects will be assigned to a treatment group upon randomization. Bayer HealthCare Pharmaceuticals personnel, investigators, subjects and study nurse/coordinators will be blinded to the study product treatment assignment. The study duration will be 24 weeks with visits at screening, baseline (week 0), week 6, week 12, week 18, and week 24. Lesion counts (total, inflammatory, non-inflammatory) and an ISGA, and photography will be performed on every visit. A physical examination will be done at baseline and Week 24. Safety will be assessed from reported adverse events (AEs).

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Acne Vulgaris
  • Drug: drospirenone and ethinyl estradiol
    Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
    Other Name: YAZ
  • Drug: Placebo tablet
    Placebo tablet (no active drug) given once daily for 24 weeks
    Other Name: Placebo
  • Active Comparator: Drosperinone and Ethinyl estradiol
    Drospirenone and Ethinyl estradiol (3mg/0.02mg)(YAZ)tablet once a day
    Intervention: Drug: drospirenone and ethinyl estradiol
  • Placebo Comparator: Placebo tablet
    Placebo tablet once a day
    Intervention: Drug: Placebo tablet
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
April 2012
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female Subjects 18-45 years of age who have achieved spontaneous menarche.
  • A clinical diagnosis of truncal acne vulgaris and the desire for an oral contraceptive for birth control.
  • A minimum of 10 but not more than 50 inflammatory lesions on the back and chest combined.
  • Maximum of 5 nodules.
  • Willing and able to understand and sign informed consent.
  • Able to complete study and comply with study procedures.

Exclusion Criteria:

  • Use of topical acne medications such as tretinoin, benzoyl peroxide or topical antibiotics within 2 weeks
  • Use of oral antibiotics within 30 days.
  • Use of systemic corticosteroids within 4 weeks.
  • Use of oral contraceptives within 12 weeks.
  • Use of isotretinoin in past six months.
  • Use of phototherapy devices for acne such as ClearLight or Zenozapper within 1 week.
  • Use of tanning booths or lamps within 1 week prior to baseline.
  • BMI >30
  • History of renal insufficiency
  • History of hepatic dysfunction
  • History of adrenal Insufficiency
  • History of vascular or metabolic disease including existing or previous arterial thromboembolic diseases (myocardial infarction, stroke), existing or previous venous thromboembolic diseases (deep vein thrombosis, pulmonary embolism), and any condition which could increase the risk to suffer any of the above mentioned disorders
  • History of hypertension
  • Diabetes mellitus with vascular involvement
  • Migraine headaches with focal neurological symptoms
  • Recent major surgery with prolonged immobilization
  • Known or suspected carcinoma of the breast
  • Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
  • Undiagnosed abnormal genital bleeding
  • Cholestatic jaundice of pregnancy or jaundice with prior pill use
  • Liver tumor (benign or malignant) or active liver disease
  • Smoking > ½ pack of cigarettes/week
  • Regular intake of medications that may increase potassium levels such as NSAIDS, potassium sparing diuretics, potassium supplementation, ACE inhibitors, Angiotensin-II receptor antagonists, heparin and aldosterone antagonists.
  • Hypersensitivity to any component of the study drug
  • Clinically significant abnormal findings or conditions (other than acne), which might, in the opinion of the Principal Investigator, interfere with study evaluations or pose a risk to subject safety during the study.
  • Subjects who are known to be pregnant or planning a pregnancy.
Female
18 Years to 45 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00722761
2008-P-000754
No
Alexandra Kimball, Massachusetts General Hospital
Massachusetts General Hospital
Bayer
Principal Investigator: Alexandra B. Kimball, MD, MPH Massachusetts General Hospital
Massachusetts General Hospital
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP